ASCO GUIDELINES Bundle

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

ASCO GUIDELINES App Bundle brought to you fcourtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1475468

Contents of this Issue

Navigation

Page 9 of 71

10 Treatment Table A2: Immunosuppressive Agents Immunosuppressive Agents Dosing Indications Nonbiological immunosuppressive agents Azathioprine (AZA) (non-selective immunosuppressant) 50 mg/day with subsequent incremental increase by 25–50 mg every 1–2 weeks up to 2 mg/kg/day Steroid-refractory immune-related hepatitis, myositis, nephritis Cyclophosphamide (CYC) (non-selective immunosuppressant) 1–2 mg/kg/day Steroid-refractory pneumonitis, nephritis, hematological irAEs Cyclosporine (Calcineurin inhibitors [CNIs]) 1–2 mg/kg/day Hematological irAEs, SCAR, and nephritis Eltrombopag (non-selective immunosuppressant) Starting dose of 50 mg daily Refractory aplastic anemia Etoposide (topoisomerase II inhibitor) 150 mg/m2 IV, twice weekly for weeks 1-2, then once weekly Severe or refractory HLH Hydroxychloroquine (non-selective immunosuppressant) 200 to 400 mg daily administered as a single dose or in two divided doses, but no more than 5 mg/kg/day calculated based upon actual body weight Mild or moderate inflammatory arthritis (cont'd)

Articles in this issue

Archives of this issue

view archives of ASCO GUIDELINES Bundle - Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy